BLU.TO Stock News Bellus Health Inc. (BLU.TO) 1.13 08/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bellus Health Inc. (BLU.TO) 1.13 $BLU.TO

BELLUS Health to Present at Bloom Burton & Co. Healthcare Investor Conference
CNW Group - Wed Jun 11, 2:02PM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company", a drug development company focused on rare diseases, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present an update on the Company's progress at the Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade on June 18, 2014 at 3:30 p.m. EDT in Toronto.

Auven Therapeutics and Bellus Health Announce Completion of Enrollment in the Phase III Confirmatory Study of Kiacta(TM) for the Treatment of AA Amyloidosis
Business Wire - Tue May 27, 4:00PM CDT
Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health Inc. (TSX:BLU), a drug development company focused on rare diseases, today announced that the KIACTA(TM) Phase III Confirmatory Study in AA amyloidosis (an orphan indication) has completed its targeted enrollment of 230 patients. Eligible patients currently in screening will also be given the opportunity to enroll in the study likely increasing total recruitment beyond 230 patients.

Auven Therapeutics and BELLUS Health announce completion of enrollment in the Phase III Confirmatory Study of KIACTA(TM) for the treatment of AA amyloidosis
CNW Group - Tue May 27, 4:00PM CDT
Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health Inc. (TSX: BLU), a drug development company focused on rare diseases, today announced that the KIACTATM Phase III Confirmatory Study in AA amyloidosis (an orphan indication) has completed its targeted enrollment of 230 patients. Eligible patients currently in screening will also be given the opportunity to enroll in the study likely increasing total recruitment beyond 230 patients.

BELLUS Health reports results for year ended December 31, 2013
CNW Group - Wed Feb 26, 6:00AM CST
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company", a drug development company focused on rare diseases, today reported its financial and operating results for the year ended December 31, 2013.

BELLUS Health provides update on KIACTA(TM) Phase III orphan drug study
CNW Group - Thu Jan 09, 6:00AM CST
-KIACTATM Study Expected to Conclude Earlier than Anticipated -

BELLUS Health announces closing of the acquisition of Thallion Pharmaceuticals
CNW Group - Thu Aug 15, 6:40AM CDT
- PIPELINE NOW FEATURES TWO CLINICAL-STAGE RARE DISEASE DRUG CANDIDATES -

Thallion Pharmaceuticals Announces Cash Component of $0.1889 Per Share
Marketwire - Fri Aug 09, 7:01AM CDT
Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement" pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health, Thallion has delivered a notice to BELLUS Health indicating that Thallion has negotiated a final and binding agreement with Iberville Development Leasing Limited pursuant to which the latter has agreed to fully, finally and irrevocably release Thallion from its obligations under the lease dated December 2, 2010, in exchange for the payment of an amount which is less than the provision for the termination of such lease included in the minimum net cash component announced on August 2, 2013. The cash component of the consideration payable on the effectiveness of the Arrangement has been increased by $0.0124 per common share resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being $0.1889 per common share.

BELLUS Health reports results for second quarter ended June 30, 2013
CNW Group - Wed Aug 07, 6:00AM CDT
- KIACTATM intellectual property position further strengthened by granting of new US patent -

Thallion Announces Shareholder Approval for Plan of Arrangement and Date and Time for the Motion for Final Court Order
Marketwire - Tue Aug 06, 4:00PM CDT
Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that the shareholders of Thallion approved the previously announced plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health at the annual and special meeting of the shareholders held today in Montreal (the "Meeting". Pursuant to the Arrangement, the Shareholders will receive cash consideration of at least $0.1765 per common share, and one contingent value right ("CVR" per common share, entitling the holder thereof to: (A) its pro rata share of 100% of any additional purchase price consideration to be received from Premium Brands Holding Corp. in 2016 (representing up to a possible $0.0404 per CVR), (B) its pro rata share of 5% of the Shigamabs(R) revenue generated or received by BELLUS Health, capped at $6.5 million (or $0.1812 per CVR), and Copyright its pro rata share of 100% of any net proceeds generated from the licensing, selling or otherwise commercializing of (i) diagnostic products or services using certain Caprion Proteomics Inc. products, and (ii) all issued patents or pending patents pertaining to such Caprion Proteomics Inc. products, in respect of which Thallion has an ownership interest or monetary entitlement.

RETRANSMISSION/Thallion Pharmaceuticals Announces Minimum Effective Net Cash of $7,500,000 Resulting in Cash Component of at Least $0.1765 Per Share
Marketwire - Fri Aug 02, 9:54AM CDT
Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement" pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health, the Effective Net Cash (within the meaning of the Acquisition Agreement) is equal to a minimum of $7,500,000 including the deemed proceeds for the exercise or cancellation and treatment as per the plan of Arrangement of "in-the-money" options of approximately $500,000, resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being at least $0.1765 per common share (the "Minimum Cash Component".

Thallion Pharmaceuticals Announces Minimum Effective Net Cash of $7,500,000 Resulting in Cash Component of at Least $0.1765 Per Share
Marketwire - Fri Aug 02, 7:01AM CDT
Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement" pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health, the Effective Net Cash (within the meaning of the Acquisition Agreement) is equal to a minimum of $7,500,000 including the deemed proceeds for the exercise or cancellation and treatment as per the plan of Arrangement of "in-the-money" options of approximately $500,000, resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being at least $0.1765 per common share (the "Minimum Cash Component".

KIACTA(TM) Granted Orphan Drug Status in Japan
CNW Group - Tue Jul 23, 6:00AM CDT
- Japanese drug development grant also received for KIACTATM -

RETRANSMISSION: BELLUS Health Amends Terms of CVRs in Connection With Its Acquisition of Thallion
Marketwire - Fri Jul 12, 4:25PM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" and Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) announced today that they have entered into an amendment (the "Amendment" to the acquisition agreement dated June 17, 2013 pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health.

BELLUS Health Amends Terms of CVRs in Connection With Its Acquisition of Thallion
Marketwire - Wed Jul 10, 6:01AM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" and Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) announced today that they have entered into an amendment (the "Amendment" to the acquisition agreement dated June 17, 2013 pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 147

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 65

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 39

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 152

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 0

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 58

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 110

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 24

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 89

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 54

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading

Top 5 Most Recently Viewed Articles

ThinkAndor® Reigns as Leading AI Platform for Virtual Care

Updated Category News Views 121

ThinkAndor® Wins Top Honors in Virtual Care Solutions Andor Health's ThinkAndor® has distinguished itself yet again as the leading **AI healthcare software infrastructure**, confirmed by recent evaluations as the best virtual care platform. This notable recognition by an acclaimed market research assessment underscores the platform's unmatched capabilities in bringing...

Continue Reading
Skanska Lands Major London Build: GBP 282M Deal

Updated Category News Views 27

A Fresh Gig in London for Skanska Skanska, the Swedish construction heavyweight is digging into London's concrete jungle with a hefty GBP 282M contract to deliver a new 23-storey commercial office building. Of course, it doesn't hurt that this project is smack-dab in the financial district, a stone's throw from the hustle and bustle of Liverpool Street Station. Looks like...

Continue Reading
Transforming Hospital Security with Innovative Visitor Management

Updated Category News Views 572

Athena Security Unveils Cutting-Edge Hospital Visitor Management System Athena Security has introduced a revolutionary Hospital Visitor Management System (VMS) designed for hospitals, providing a robust layer of security with constant operational capabilities. Controlled from a 13-inch iPad, this new system offers resilience, operating around the clock, regardless of...

Continue Reading
Clarios Partners with Scientix to Advance STEM Education

Updated Category News Views 143

Clarios Collaborates with Scientix for Sustainable STEM Education Clarios, a global leader in advanced low-voltage battery solutions and the proud home of VARTA Automotive, is excited to announce its new partnership with European Schoolnet as part of the Scientix STEM Alliance. This alliance aims to promote education in STEM (Science, Technology, Engineering, and...

Continue Reading
SCOR Maintains Timeline for 2022 Arbitration on Retrocession Treaties

Updated Category News Views 151

Overview of SCOR's Arbitration Regarding Retrocession Treaties In the evolving landscape of global reinsurance, SCOR has been actively involved in legal proceedings concerning retrocession treaties. The arbitration in question, initiated in 2022, responds to a request for enforcing treaties signed with Covéa back in June 2021. Status of the Arbitration Proceedings As...

Continue Reading